Lysine as a Potential Low Molecular Weight Angiogen: its Clinical, Experimental and In-Silico Validation- a Brief Study

Author(s): Debatosh Datta, Priyanshu Verma, Anindita Banerjee, Partha Pratim Mukherjee, Debashis Ganguly, Sujoy Kar, Tanima Sengupta, Nalinava Sengupta, Sujoy Kumar Samanta, Enam Murshed Khan

Globally, the area of angiogenesis is dominated by investigations on anti-angiogenic agents and processes, due to their role in metastatic cancer treatment although the nearly non-existent area of pro-angiogenesis or inducible controlled angiogenesis in ischemic tissue reperfusion is having much bigger potential demand and far wider clinical footmark. Following clinical failure of VEGF (Vascular endothelial growth factor) as a potential agent for induction of a controlled angiogenic response in ischemic tissues and organs, the progress is reasonably quiet as for new low molecular weight (LMW) angiogen molecules and their clinical applications. Basic amino acid Lysine has been observed to have profound angiogenic property in ischemic tissues, which is controlled, reproducible, time bound and without any accompanying reperfusion-reentry damage. In this study, the basic amino acid Lysine has been suggested as a LMW-angiogen (low mol wt angiogen) and it has been proposed to have a molecular bridging role between VEGF and VEGF receptor (VEGFR). Here, the molecular adhesive hypothesis is being probed and confirmed both in the clinical and lab conditions through induced angiogenic response in tissue repair and in chick chorioallantoic membrane (CAM), respectively; and in dry-docking experiments (in-silico studies)